25 results on '"Kelly, W.K."'
Search Results
2. c-Met is a prognostic marker and potential therapeutic target in clear cell renal cell carcinoma
3. 1610P Circulating tumour cell (CTC) enumeration and overall survival (OS) in men with metastatic castration-resistant prostate cancer (mCRPC) treated with xaluritamig
4. 1598P Xaluritamig, a STEAP1 x CD3 XmAb 2+1 immune therapy, in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC): Initial results from dose expansion cohorts in a phase I study
5. A phase 1 study of AMG 509 in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC).
6. Efficacy of carboplatin–taxane combinations in the management of castration-resistant prostate cancer: a pooled analysis of seven prospective clinical trials
7. 264P Interim results from a phase I study of AMG 509 (xaluritamig), a STEAP1 x CD3 XmAb 2+1 immune therapy in patients with metastatic castration-resistant prostate cancer (mCRPC)
8. Pilot study of epothilone B analog (BMS-247550) and estramustine phosphate in patients with progressive metastatic prostate cancer following castration
9. PROSTATE CANCER TREATMENT AND THE RISK OF SEPTICEMIA
10. SHORT-TERM OUTCOMES FOLLOWING ORAL HORMONAL PROSTATE CANCER THERAPIES BY PRE-EXISTING CARDIOVASCULAR CONDITIONS: A POPULATION-BASED STUDY
11. Pre-specified interim analysis of GALAHAD: A phase II study of niraparib in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) and biallelic DNA-repair gene defects (DRD)
12. Urine extracellular vesicle GATA2 mRNA alone and in a multigene test predicts initial prostate biopsy result
13. First Prospective Results Assessing the Clinical Utility and Clinical Benefit of Genomic Classifier Testing in Men Post-Prostatectomy
14. Can Genomic Classifiers Be Used to Identify Those Appropriate for Observation Despite High Risk Pathologic Features Following Radical Prostatectomy?
15. Role of genetic testing for inherited prostate cancer risk: Philadelphia prostate cancer consensus conference 2017
16. Naming disease states for clinical utility in prostate cancer: a rose by any other name might not smell as sweet
17. P075 - SHORT-TERM OUTCOMES FOLLOWING ORAL HORMONAL PROSTATE CANCER THERAPIES BY PRE-EXISTING CARDIOVASCULAR CONDITIONS: A POPULATION-BASED STUDY
18. LBA50 - Pre-specified interim analysis of GALAHAD: A phase II study of niraparib in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) and biallelic DNA-repair gene defects (DRD)
19. 887P - Urine extracellular vesicle GATA2 mRNA alone and in a multigene test predicts initial prostate biopsy result
20. BCL-2 antisense (G3139) plus docetaxel for treatment of progressive androgen-independent prostate cancer
21. Bicalutamide for Advanced Prostate Cancer: The Natural Versus Treated History of Disease
22. Endocrine Withdrawal Syndrome and Its Relevance to the Management of Hormone Refractory Prostate Cancer
23. Case Reports: Withdrawal Phenomenon With the Antiandrogen Casodex
24. Case Reports: Withdrawal Phenomenon With the Antiandrogen Casodex
25. O08 - PROSTATE CANCER TREATMENT AND THE RISK OF SEPTICEMIA.
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.